Skip to content
E0 · Evidence synthesisReviewPEM unclearSystematic reviewPeer-reviewed
Standard · 3 min

Outcome measures in long COVID clinical trials: a review.

van Rhijn-Brouwer, Femke C C, de Canson, Chloé, VanDerNagel, Joanneke E L et al.

Frontiers in public health2026DOIPubMed

Design
Systematic review
Participants
Not reported
PEM required
Unclear
Case definition
Not stated in the abstract

Quick Summary

Researchers reviewed clinical trials for long COVID and ME/CFS to see what measures doctors and researchers use to track whether treatments work. They found that trials use many different outcome measures, and report that long COVID trials could be improved by better measuring specific symptoms like post-exertional malaise and dysautonomia, and by including what patients think matters most. This is an early review of current practices, not a definitive guide.

Why It Matters

By analogy, this review matters for ME/CFS because the authors explicitly note significant overlap between long COVID and ME/CFS pathophysiology and symptom profiles. The findings suggest that ME/CFS clinical trials, like long COVID trials, may benefit from outcome measures more specifically targeting post-exertional malaise and related dysregulation patterns. This work may help guide future ME/CFS trial design by highlighting which outcome measures are currently underused or absent in the field.

Observed Findings

What the study reports it measured.

  • Systematic review identified 397 outcome measures across 37 ME/CFS and 68 long COVID clinical trials, indicating heterogeneity in measurement practices.
  • Post-exertional malaise, dysautonomia, and mast cell activation symptom clusters were observed to be underrepresented or absent in many long COVID trials reviewed.
  • Long COVID trials were observed to vary widely in whether they incorporated patient-reported outcomes, clinical assessments, physical tests, and biomarkers.
  • Safety of interventions was observed to be rarely adequately evaluated across the trials examined.
  • The authors noted significant clinical and symptomatic overlap between long COVID and ME/CFS trial populations, suggesting potential transferability of trial design lessons.

Inferred Conclusions

What the authors interpret from those results.

  • The authors interpret the findings as indicating that long COVID trial design would benefit from more systematic measurement of post-exertional malaise and related dysregulation phenomena, drawing on prior ME/CFS trial experience.
  • They conclude that integrating patient input throughout trial design, execution, and evaluation could improve the relevance and applicability of outcome measures to patient priorities.
  • The authors suggest that combining patient-reported outcomes with objective clinical assessments and biomarkers may strengthen trial design, provided feasibility and safety are confirmed in each context.

Remaining Questions

  • Which outcome measures most accurately predict clinically meaningful improvement in long COVID or ME/CFS?
  • How should post-exertional malaise and dysautonomia be standardised and operationalised across clinical trials to enable comparability?
  • What role should biomarkers play in long COVID and ME/CFS trials, given current uncertainty about mechanistic specificity?
  • How can patient engagement in trial design be implemented without introducing bias or delaying trial initiation?

What This Study Does Not Prove

This review does not establish which outcome measures actually predict clinical benefit or disease progression in ME/CFS or long COVID. It does not compare the validity or responsiveness of different measures in a prospective trial. It does not prove that any current treatment is safe or effective; it only surveys how existing trials measure outcomes. The applicability of long COVID trial design recommendations to ME/CFS clinical trials remains to be tested.

Explore further

About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →

Cite this study

The first block is for the primary paper and is the citation you should use in research work. The atlas-snapshot line only applies if you are specifically referring to this atlas’s reading of the paper on the date shown.

Primary citation

van Rhijn-Brouwer, Femke C C, de Canson, Chloé, VanDerNagel, Joanneke E L, Westerhuis, Xandra, Young, Susanne Y, van Kuijk, Sander M J, et al. (2026). Outcome measures in long COVID clinical trials: a review.. Frontiers in public health. https://doi.org/10.3389/fpubh.2026.1972605

BibTeX

@article{mecfsatlas-van-rhijn-brouwer-2026-outcome-measures,
  author  = {van Rhijn-Brouwer, Femke C C and de Canson, Chloé and VanDerNagel, Joanneke E L and Westerhuis, Xandra and Young, Susanne Y and van Kuijk, Sander M J and de Vries, Laura V and van Rhijn, Jon-Ruben and Hellemons, Merel},
  title   = {Outcome measures in long COVID clinical trials: a review.},
  journal = {Frontiers in public health},
  year    = {2026},
  doi     = {10.3389/fpubh.2026.1972605},
  note    = {PubMed: 42973774},
  url     = {https://www.mecfsatlas.com/evidence/van-rhijn-brouwer-2026-outcome-measures},
}

Atlas snapshot reference

ME/CFS Atlas. Generator v1 / Scanner v1.4 / policy v0.1. Accessed 2026-11-13. https://www.mecfsatlas.com/evidence/van-rhijn-brouwer-2026-outcome-measures

Contribute

Private, reviewed by a human. Not a public comment thread.